Allorion Therapeutics Massachusetts California
07.08.2025 - 18:00:21Avenzo Therapeutics Announces Global License of AVZO-021 , a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
About Avenzo Therapeutics, Inc.
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of oncology therapies for patients. The company's lead drug candidate, AVZO-021, is a novel, highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. AVZO-021 is being studied in a Phase 1 study in the U.S. for the treatment of advanced solid tumors. Avenzo is headquartered in San Diego, California. For more information, visit us at www.avenzotx.com or on LinkedIn.
About Allorion Therapeutics Inc.
Allorion Therapeutics is a clinical-stage biotechnology company that focuses on creating new small molecule drugs for treating cancer and autoimmune diseases. The company has a team of experienced drug discovery and development professionals who identify new drugs with unique mechanisms of actions and develop innovative data and screening platforms for long-term success. Allorion Therapeutics aims to advance new drugs with high potential and clinical relevance.
Avenzo Therapeutics Contact:
Media Relations
media@avenzotx.com
Allorion Therapeutics Contact:
Media Relations
media@alloriontx.com
Logo - https://mma.prnewswire.com/media/2245014/Allorion_Logo.jpg
View original content:
